Evidence map›Paper›PMID 32636840›Full record

ArticleFrontiers in immunology2020

A Novel Synthetic Dual Agonistic Liposomal TLR4/7 Adjuvant Promotes Broad Immune Responses in an Influenza Vaccine With Minimal Reactogenicity.

Fumi Sato-Kaneko, Shiyin Yao, Fitzgerald S Lao, Jonathan Shpigelman, Karen Messer, Minya Pu, Nikunj M Shukla, Howard B Cottam, Michael Chan, Paul J Chu and 6 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in immunology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.

0numbers the graph read from it
0cells of the map it votes in
21citing papers in PubMed
2.3field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

21 citing papers in PubMed, 28 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. Review
  9. Review
  10. Review
  11. Article
  12. Review
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Mitochondria-dependent synthetic small-molecule vaccine adjuvants for influenza virus infection.Proceedings of the National Academy of Sciences of the United States of America · 2021
    Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 2 institutions in 2 countries.

Fumi Sato-KanekoMoores Cancer Center, University of California, San Diego, La Jolla, CA, United States.
Shiyin YaoMoores Cancer Center, University of California, San Diego, La Jolla, CA, United States.
Fitzgerald S LaoMoores Cancer Center, University of California, San Diego, La Jolla, CA, United States.
Jonathan ShpigelmanMoores Cancer Center, University of California, San Diego, La Jolla, CA, United States.
Karen MesserDivision of Biostatistics, University of California, San Diego, La Jolla, CA, United States.
Minya PuDivision of Biostatistics, University of California, San Diego, La Jolla, CA, United States.
Nikunj M ShuklaMoores Cancer Center, University of California, San Diego, La Jolla, CA, United States.
Howard B CottamMoores Cancer Center, University of California, San Diego, La Jolla, CA, United States.
Michael ChanMoores Cancer Center, University of California, San Diego, La Jolla, CA, United States.
Paul J ChuMoores Cancer Center, University of California, San Diego, La Jolla, CA, United States.
David BurkhartInimmune Corp., Missoula, MT, United States.
Roman SchoenerInimmune Corp., Missoula, MT, United States.
Takaji MatsutaniRepertoire Genesis Inc., Saito-Asagai, Osaka, Japan.
Dennis A CarsonMoores Cancer Center, University of California, San Diego, La Jolla, CA, United States.
Maripat CorrDepartment of Medicine, University of California, San Diego, La Jolla, CA, United States.
Tomoko HayashiMoores Cancer Center, University of California, San Diego, La Jolla, CA, United States.
University of California, San Diego · USGenesis Research Institute · JP

Funding

TO IDENTIFY NOVEL ADJUVANT CANDIDATES THAT CAN BE USED TO AUGMENT THE EFFICACY OF HUMAN VACCINES.75N93019C00042 · NIAID · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI CARSON, DENNIS · 2019 to 2024
$10.2M
NIAID NIH HHS 75N93019C00042NIAID NIH HHS HHSN272201400051C
6 · The paper itself

Abstract

The limited efficacy of seasonal influenza vaccines is usually attributed to ongoing variation in the major antigenic targets for protective antibody responses including hemagglutinin (HA) and neuraminidase (NA). Hence, vaccine development has largely focused on broadening antigenic epitopes to generate cross-reactive protection. However, the vaccine adjuvant components which can accelerate, enhance and prolong antigenic immune responses, can also increase the breadth of these responses. We previously demonstrated that the combination of synthetic small-molecule Toll-like receptor 4 (TLR4) and TLR7 ligands is a potent adjuvant for recombinant influenza virus HA, inducing rapid, and sustained antibody responses that are protective against influenza viruses in homologous and heterologous murine challenge models. To further enhance adjuvant efficacy, we performed a structure-activity relationship study for the TLR4 ligand,

Indexed as

Adjuvants, ImmunologicAnimalsAntibodies, ViralHemagglutinin Glycoproteins, Influenza VirusHumansInfluenza A Virus, H1N1 SubtypeInfluenza VaccinesLiposomesMiceNeuraminidaseOrthomyxoviridae InfectionsToll-Like Receptor 4Toll-Like Receptor 7Adjuvants, ImmunologicAntibodies, ViralHemagglutinin Glycoproteins, Influenza Virushemagglutinin, human influenza A virusInfluenza VaccinesLiposomesNeuraminidaseToll-Like Receptor 4Toll-Like Receptor 7combination adjuvantinfluenza virus infectionsmall moleculesynthetic TLR4 agonistsynthetic TLR7 agonistsvaccine

Identifiers

PMID32636840
PMCPMC7318308
OpenAlexW3026795897

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.